Carvedilol (versus unexposed) updated on 12-17-2024

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17236
R72138		 Kubota - Carvedilol, 2023 Small for gestational age (birth weights evaluated using the new standard value of physique at birth by gestational age) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.36 [0.73;7.61] C 4/32   15/263 19 32
ref
S14076
R55411		 Tanaka, 2016 Fetal growth restriction (considered equivalent to light for gestational age, birth weight <10th percentile for gestational age) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: Yes Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.36 [0.23;21.91] 1/13   3/100 4 13
ref
Total 2 studies 2.36 [0.83;6.69] 23 45
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kubota - Carvedilol, 2023Kubota - Carvedilol, 2023 2.36[0.73; 7.61]193279%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: critical Tanaka, 2016Tanaka, 2016 2.36[0.23; 21.91]41321%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.36[0.83; 6.69]23450.95.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.36[0.83; 6.69]23450%NAKubota - Carvedilol, 2023 Tanaka, 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.36[0.83; 6.69]23450%NAKubota - Carvedilol, 2023 Tanaka, 2016 2 Tags Adjustment   - No  - No 2.36[0.73; 7.61]1932 -NAKubota - Carvedilol, 2023 1   - Yes  - Yes 2.36[0.24; 23.03]413 -NATanaka, 2016 1 Indications Antihypertensive   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.36[0.83; 6.69]23450%NAKubota - Carvedilol, 2023 Tanaka, 2016 2 All studiesAll studies 2.36[0.83; 6.69]23450%NAKubota - Carvedilol, 2023 Tanaka, 2016 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.36[0.83; 6.69]23450%NAKubota - Carvedilol, 2023 Tanaka, 2016 20.510.01.0